Endometriosis pain can be difficult to describe to someone who has never experienced it. For some patients, it means intensely painful menstrual cramps. For others, it produces chronic pelvic aching, stabbing sensations, pain during intercourse, painful bowel movements, bladder symptoms, lower-back discomfort, or pain that persists even outside menstruation. The American College of Obstetricians and Gynecologists (ACOG) describes endometriosis as a chronic inflammatory disorder involving endometrial-like tissue outside the uterus, and recognizes that the condition can cause severe pain, infertility, and major reductions in quality of life. Updated ACOG guidance published in 2026 also emphasizes that patients should not necessarily have to wait for surgery before clinicians begin evaluating and treating suspected disease.
Medical marijuana has attracted considerable interest among people whose symptoms continue despite hormonal therapy, pain medication, surgery, or combinations of these treatments. Cannabis is particularly intriguing because the body’s endocannabinoid system is involved in pain signaling, inflammation, nerve activity, and reproductive biology. Yet there is an important divide between biological plausibility and clinical proof. Surveys and observational studies repeatedly find that patients with endometriosis report substantial relief after cannabis use, while the first meaningful randomized evidence examining CBD has been far less encouraging. ACOG’s current clinical consensus consequently states that there is insufficient evidence to recommend cannabis products for gynecologic pain, including endometriosis-associated pain.
Why Endometriosis Pain Can Be So Difficult to Treat
Endometriosis pain is not necessarily produced by a single mechanism. Lesions and associated inflammatory activity can generate nociceptive pain, adhesions may mechanically affect pelvic structures, and endometriosis lesions can develop extensive nerve supplies. Repeated pain over months or years may also alter how the peripheral and central nervous systems process sensory signals. This helps explain why the amount of visible disease does not always correspond neatly with pain severity and why surgery does not guarantee permanent symptom relief.
The European Society of Human Reproduction and Embryology‘s endometriosis guideline recognizes several established approaches to endometriosis-associated pain. Analgesics such as NSAIDs may be considered, while hormonal options include combined hormonal contraceptives, progestogens, GnRH agonists, GnRH antagonists, and—in selected refractory cases—aromatase inhibitors. Surgery is another option, and postoperative hormonal treatment may sometimes be considered to reduce recurrence of symptoms. Treatment selection is individualized according to effectiveness, adverse effects, availability, reproductive goals, and patient preferences.
None of those treatments works equally well for every patient. Hormonal therapies may produce unwanted adverse effects or may conflict with attempts to conceive. Pain can recur following surgery, and long-term reliance on conventional analgesics carries its own limitations. This therapeutic gap is one reason cannabis use has become relatively common among people living with endometriosis—even though medical evidence has not yet caught up with patient interest.
Why Scientists Are Interested in the Endocannabinoid System
Cannabis contains numerous biologically active compounds, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) receiving the most attention. THC activates cannabinoid CB1 receptors relatively directly and is responsible for most cannabis intoxication. CBD does not produce a conventional marijuana high and interacts much more indirectly with the endocannabinoid system and several other molecular targets.
Research from the University of Queensland and collaborating institutions has highlighted the potential relevance of this system to endometriosis. Components of the endocannabinoid system—including CB1 and CB2 cannabinoid receptors, endogenous cannabinoid molecules, and the enzymes responsible for producing and breaking them down—are found within reproductive tissues. Researchers have also identified cannabinoid receptors within deep endometriotic lesions and within nerves supplying those lesions. These findings provide a credible biological reason to investigate cannabinoid signaling as a possible target for endometriosis research.
That evidence should not be interpreted as proof that marijuana eliminates endometriosis. Much of the research investigating cannabinoids, inflammation, lesion proliferation, angiogenesis, cellular migration, and endometriotic tissue comes from laboratory or animal experiments. A review examining CBD specifically for endometriosis concluded that some preclinical experiments appear promising, but results have been inconsistent and cannot automatically be extrapolated to patients. Cannabis might alter pain perception without changing the underlying lesions at all. At present, there is no convincing human evidence that marijuana causes endometriosis lesions to shrink, prevents progression, or cures the disease.
What People With Endometriosis Report About Cannabis
Patient-reported studies have generated some of the most positive findings. One retrospective study analyzed more than 16,000 cannabis-use sessions recorded by 252 people who identified as having endometriosis. Pelvic pain was the most frequently treated symptom, while gastrointestinal problems, cramps, nausea, mood symptoms, and other complaints were also recorded. Users reported reductions in symptom severity after cannabis consumption. Inhaled products appeared to produce greater reported improvements in pain, whereas oral products performed somewhat better for gastrointestinal and mood-related symptoms. Because participants selected their own cannabis and recorded their own outcomes, however, the study cannot determine how much improvement was caused by cannabis rather than expectation, selection bias, natural changes in symptoms, or other treatments.
Survey results from Australia, New Zealand, and Europe tell a similar story. A German-language survey involving more than 900 respondents found that among the subgroup using cannabis for self-management, sleep, menstrual pain, and noncyclic pelvic pain were among the symptoms most often reported as improving. Approximately 90% of cannabis users in that survey reported reducing their use of pain medication. Another New Zealand survey found very high rates of self-reported improvement in pain and sleep and reductions in pharmaceutical analgesic use. These findings are important because they consistently describe what patients themselves are experiencing, but surveys cannot establish efficacy the way randomized placebo-controlled trials can.
ACOG reached essentially that conclusion in its 2024 Clinical Consensus on cannabis for gynecologic pain. The organization acknowledged that patients with endometriosis and chronic pelvic pain commonly report benefits involving pain, cramping, muscle spasms, sleep, mood, and other symptoms. Some also report reducing opioid or other analgesic use. But the evidence is mainly observational and self-reported, and ACOG states that the data remain insufficient to recommend cannabis as a treatment for gynecologic pain.
A 2026 University Study Found Improvements With Prescribed Cannabis
A prospective study published in January 2026 adds stronger—but still uncontrolled—evidence. Researchers from the University of Otago, Western Sydney University, Griffith University, Deakin University, and the Medical Research Institute of New Zealand followed 28 adults with clinically or surgically diagnosed endometriosis who were beginning prescribed medicinal cannabis. Participants received CBD oil alone or CBD oil together with dried cannabis flower and were followed for 12 weeks.
Average overall pelvic-pain scores declined from approximately 5.46 to 3.77 on a 10-point scale, while worst-pain scores declined from approximately 7.62 to 5.38. Quality of life, measured using the Endometriosis Health Profile-30, also improved substantially during the study. Reported adverse events were comparatively limited, with headaches reported by three participants and isolated reports of fatigue and drowsiness.
Those results are encouraging, but there was no placebo comparison group. Everyone knew they were receiving medicinal cannabis, prescribing was individualized, and the cohort contained only 28 participants. Symptoms can fluctuate naturally, concurrent treatments can influence outcomes, and expectations surrounding a new treatment can produce substantial placebo responses. The researchers therefore described the findings as support for larger controlled studies rather than proof that cannabis is an effective endometriosis therapy.
The Randomized CBD Trial Produced a Very Different Result
Perhaps the most important development in the evidence arrived in 2026 from researchers at the University of São Paulo. The DREAMLAND study was a triple-blind, randomized, placebo-controlled trial involving 102 patients with surgically confirmed endometriosis who had undergone surgery, remained on hormonal treatment, and experienced recurring symptoms. Fifty-one participants received cannabidiol-enriched oil and 51 received placebo. CBD doses were gradually increased during a planned 10-week treatment period, ultimately reaching doses as high as 150 mg per day.
The results challenge the idea that CBD alone is a proven endometriosis pain reliever. About 40% of participants in both groups experienced at least a 50% reduction in pain, while roughly 60% in both groups achieved at least a 30% improvement. At the end of treatment, average pain was actually numerically lower in the placebo group, although the difference was not statistically significant. The CBD group did show improvement in some psychological and quality-of-life measures, but it also experienced more mild adverse events, particularly gastrointestinal symptoms and perceived weight changes. Investigators stopped the study after the planned interim analysis because CBD was not demonstrating a clinically relevant advantage over placebo.
This trial substantially changes how CBD for endometriosis should be discussed. Earlier surveys often combined THC-containing cannabis, CBD products, and multiple routes of administration, making it impossible to determine which constituent was producing the reported benefit. The DREAMLAND trial specifically tested CBD under controlled conditions and found no superior pain relief compared with placebo. That does not establish that CBD can never help an individual patient, but it means claims that CBD oil has been clinically proven to treat endometriosis pain are not supported by the strongest direct evidence currently available.
What About THC or THC and CBD Together?
THC remains a different question. The University of São Paulo trial evaluated CBD-enriched oil rather than a conventional THC-containing cannabis product. Broader chronic-pain research suggests that products containing THC have generally produced more consistent analgesic signals than CBD alone. The National Center for Complementary and Integrative Health notes that cannabis and cannabinoid research shows modest potential benefit for chronic pain, particularly certain neuropathic pain conditions, but adverse events occur more frequently than with placebo.
Direct endometriosis trials involving THC remain remarkably limited. Researchers from Western Sydney University, Deakin University, and collaborating institutions attempted a three-arm randomized feasibility trial comparing vaporized cannabis containing 16% THC plus CBD oil, CBD oil alone, and placebo. The researchers hoped to enroll 63 participants but randomized only 12; seven withdrew and just four completed the study. The trial therefore could not establish efficacy. Recruitment difficulties were driven partly by restrictions on driving while participating, illustrating one of the practical complications involved in studying THC-containing medicine.
For now, there is therefore no scientifically established THC dose, CBD dose, THC ratio, strain, terpene profile, or method of administration that can be called best for endometriosis. Patient surveys may generate hypotheses about inhaled versus oral products or THC versus CBD, but they cannot establish treatment standards.
What Clinical Guidelines Say About Cannabis and Endometriosis
ACOG’s position is particularly important because its 2024 Clinical Consensus addresses cannabis for gynecologic pain directly. The organization concludes that better-quality evidence is needed and that available data are insufficient to recommend cannabis products for gynecologic pain. Clinicians are encouraged to discuss both the theoretical benefits associated with the endocannabinoid pathway and the known adverse effects and uncertainties surrounding cannabis products. ACOG also states that existing evidence is not strong enough to support substituting cannabis for established pain medication solely on the basis of observational reports.
The ESHRE guideline likewise does not list cannabis as an established endometriosis treatment. Its evidence-based options include analgesics, hormonal suppression, selected second-line hormonal therapies, surgery, and individualized nonmedical strategies designed to support quality of life. Treatment should involve shared decision-making and consider symptoms, side effects, reproductive plans, costs, availability, and patient preferences.
This distinction is important. Medical cannabis may be legal for chronic pain or other qualifying conditions in some jurisdictions, but legal medical access is not the same thing as clinical guideline endorsement for endometriosis. In the United States, the FDA has not approved marijuana, THC, or CBD specifically for endometriosis. A patient may nevertheless discuss cannabinoid use with a clinician as part of an individualized chronic-pain strategy, particularly when conventional treatments have produced inadequate relief or unacceptable adverse effects.
Risks, Fertility, Pregnancy, and Medication Interactions
THC-containing cannabis can cause dizziness, impaired attention, slowed reaction time, anxiety, changes in memory, sedation, and intoxication. These effects become particularly relevant with high-potency products and frequent use. ACOG additionally warns that adolescents face greater concern regarding cognitive and psychiatric effects and states that available evidence is not adequate to recommend medical cannabis for adolescents with gynecologic pain.
CBD does not produce the same intoxication, but it should not be regarded as biologically inactive. The FDA warns that CBD can cause liver injury, sedation, and clinically relevant drug interactions. CBD can alter enzymes responsible for metabolizing other medications, making medication review particularly important for people using multiple prescriptions. Commercial CBD products also vary in composition and may contain different amounts of cannabinoids or contaminants than consumers expect.
Reproductive plans require additional caution because endometriosis itself is associated with infertility and many patients are actively trying to conceive. The FDA strongly advises against marijuana, THC, and CBD during pregnancy and breastfeeding because of potential fetal and infant risks and major gaps in safety research. Cannabis should therefore not be assumed to be a fertility-neutral substitute for hormonal endometriosis therapy simply because it does not suppress ovulation in the same manner. Anyone considering pregnancy should discuss cannabis use with their obstetrician-gynecologist or fertility specialist.
Where Medical Marijuana May Fit in Endometriosis Care
Current evidence makes the strongest case for viewing medical marijuana as a possible adjunctive symptom-management option, not a disease-modifying treatment. Some adults with persistent pelvic pain report meaningful reductions in pain, cramping, sleep disturbance, nausea, gastrointestinal symptoms, or reliance on other analgesics. Prospective university research also shows encouraging improvement in pain and quality-of-life measures when prescribed cannabis is followed over several months. Those findings justify continued clinical research and respectful conversations between patients and healthcare professionals.
They do not justify promising that marijuana will treat the underlying endometriosis. The strongest randomized CBD evidence is negative, THC-containing therapies remain inadequately tested specifically for this disease, and major professional guidelines have not endorsed cannabis as standard therapy. Medical cannabis also should not delay evaluation of worsening pelvic pain, new bowel or urinary symptoms, heavy bleeding, fertility problems, or symptoms that could indicate another gynecologic condition.
For selected adults whose endometriosis pain remains difficult to manage despite conventional care, a clinician may reasonably discuss the existing cannabinoid evidence alongside established therapies, other medications, mental-health history, pregnancy plans, occupational and driving requirements, and the patient’s personal goals. That is considerably different from treating cannabis as a first-line or universally appropriate remedy.
Final Thoughts on Medical Marijuana for Endometriosis Pain
Medical marijuana for endometriosis sits in an unusual position scientifically. Patient experience is consistently more positive than controlled clinical evidence. Thousands of self-reported cannabis experiences suggest that some people obtain substantial relief from pelvic pain, menstrual pain, sleep disturbance, gastrointestinal symptoms, and other endometriosis-related problems. A 2026 prospective study involving University of Otago and Western Sydney University researchers also recorded meaningful improvements in pain and quality of life during three months of prescribed medicinal cannabis use.
Yet the 2026 University of São Paulo randomized trial found that CBD-enriched oil did not relieve endometriosis pain better than placebo, providing an important reminder that observational improvement does not necessarily establish pharmacological efficacy. THC-containing cannabis remains less well tested directly in endometriosis, and attempts to conduct controlled trials have faced major recruitment and practical difficulties.
The most evidence-based conclusion in 2026 is therefore not that cannabis works or does not work for endometriosis. It is that some patients clearly report benefit, the biological rationale deserves serious investigation, but researchers have not yet identified a cannabinoid treatment with convincing randomized evidence for endometriosis pain. Until larger controlled trials determine whether THC, THC/CBD combinations, or other cannabinoid therapies meaningfully outperform placebo and established care, medical marijuana is best regarded as an individualized, still-investigational option for symptom relief rather than a proven treatment for endometriosis itself.
